Therapeutic DLL4 binding proteins
US9469688B2 · kind B2 · utility
2Cited by
100References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2015 |
| Grant date | Oct 18, 2016 |
| Priority date | — |
| Expiry date | Aug 10, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.